India, Oct. 1 -- Thursday, Candel Therapeutics (CADL) reported final Phase 2a data for aglatimagene besadenovec plus valacyclovir in patients with unresectable Stage III/IV non-small cell lung cancer (NSCLC) who had an inadequate response to immune checkpoint inhibitors (ICIs).
Aglatimagene is an investigational multimodal biological immunotherapy designed to stimulate a systemic anti-tumor immune response against injected tumors and distant metastases.
The findings were published in the Journal for ImmunoTherapy of Cancer.
Phase 2a Trial
The Phase 2a trial enrolled patients with advanced NSCLC who had shown an inadequate response to ICI therapy. The evaluable population included 46 patients who received two courses of aglatimagene plus...